Infliximab

New Data Show Statistically Greater Improvements in Clinical Outcomes with Subcutaneous Infliximab, Compared to Intravenous Infliximab, in Patients With Rheumatoid Arthritis

Retrieved on: 
Mardi, mai 31, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Joint, Royal commission, Product, Toulouse III - Paul Sabatier University, Disease, NRI, Immune system, The American Journal of Managed Care, Randomized controlled trial, Pain, Swelling, European Commission, Degenerative disease, EULAR, CGMP, EC, Celltrion, III, Observation, Poster, Biosimilar, US Foods, Medication package insert, IV, Adult, Rheumatoid arthritis, FDA, IBD, Infliximab, Inflammatory bowel disease, Rheumatology, Congress, American Journal, Senior, Disease-modifying antirheumatic drug, Risk, Population, European Medicines Agency, Patient, Human, RA, Marketing, Diagnosis, Medical device, Pharmaceutical industry, EU

The post-hoc study investigated whether the numerical advantage of SC infliximab compared to IV, shown in most efficacy parameters at weeks 30 and 54, was statistically significant.

Key Points: 
  • The post-hoc study investigated whether the numerical advantage of SC infliximab compared to IV, shown in most efficacy parameters at weeks 30 and 54, was statistically significant.
  • Results showed a statistically significant difference in favour of SC compared to IV-treated patients at week 30 in almost all clinical variables, including low disease activity rates and remission rate.
  • Efficacy of Subcutaneous Infliximab (CT-P13 SC) Compared with Intravenous Infliximab in Rheumatoid Arthritis: A Post-hoc Analysis of a Phase 3 Randomized Controlled Trial.
  • A novel formulation of CT-P13 (infliximab biosimilar) for subcutaneous administration: 30-week results from part two of a Phase I/III randomised controlled trial in patients with rheumatoid arthritis.

Biosimilar Monoclonal Antibodies Global Market Research Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Lundi, mai 30, 2022
Biotechnology, Pharmaceutical, Health, Biosimilar, Compound, Conditional sentence, Food, US Foods, Rituximab, Incidence, Degenerative disease, Leadership, European Medicines Agency, TL, AbbVie, Patient, Trastuzumab, Government, Therapy, Bevacizumab, Pfizer, Novartis, Infliximab, EMA, Celltrion, Immunity, Sri Aurobindo, Autoimmune disease, Safety, Organization, American Cancer Society, Abciximab, Rheumatoid arthritis, Boehringer Ingelheim, Aurobindo Pharma, ACS, Cancer, Prevalence, Growth, Application, Adalimumab, Generic drug, Fine chemical, Vaccine, Allergan

The "Biosimilar Monoclonal Antibodies Global Market Report 2022: By Type, By Application, By Compound" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Biosimilar Monoclonal Antibodies Global Market Report 2022: By Type, By Application, By Compound" report has been added to ResearchAndMarkets.com's offering.
  • Biosimilar Monoclonal Antibodies Global Market Report 2022 provides the strategists, marketers and senior management with the critical information they need to assess the global biosimilar monoclonal antibodies market.
  • The biosimilar monoclonal antibodies market consists of sales of biosimilar monoclonal antibodies and related services by entities (organizations, sole traders and partnerships) that produce biosimilar monoclonal antibodies, which are used to treat patients with chronic diseases such as cancer, rheumatoid arthritis, and autoimmune disease.
  • Global Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
    6.2.

Fzata Winner of Mid-Atlantic Innovation Celebration, Biotechnology

Retrieved on: 
Vendredi, mai 20, 2022
Diabetes, Inflammation, NOVA, Company, Disease, Infection, Fairfax, Multimedia, Policy, Chamber of commerce, Injection, Clinical trial, Trial of the century, Clostridioides difficile infection, NIH, IBD, Inflammatory bowel disease, Morale, Biomarker, Biotechnology, Degenerative disease, Therapy, Commerce, Adalimumab, Clostridioides, Cancer, Northern Virginia Chamber of Commerce, CEO, Vaccine, Pharmaceutical industry, Infliximab, Washington metropolitan area

HALETHORPE, Md., May 20, 2022 /PRNewswire/ -- Fzata, Inc., a biotech innovator, is proud to announce that it has been named the winner of the 2022 Mid-Atlantic Innovation Celebration for Biotechnology for its oral Bioengineered Probiotic Yeast Medicines(BioPYM)platform.

Key Points: 
  • HALETHORPE, Md., May 20, 2022 /PRNewswire/ -- Fzata, Inc., a biotech innovator, is proud to announce that it has been named the winner of the 2022 Mid-Atlantic Innovation Celebration for Biotechnology for its oral Bioengineered Probiotic Yeast Medicines(BioPYM)platform.
  • Innovators can be almost anything, from cutting-edge products that solve business needs to creative shifts that improve employee morale.
  • Fzata is a near-clinical stage platform biopharmaceutical company in the BioHealth Capital Region.
  • Fzata is now raising $10M to support the inflammatory bowel disease (IBD) BioPYM program throughphase 1 clinical trial.

Nufactor Receives URAC's Leaders in Performance Measurement 2021 Pioneer Award

Retrieved on: 
Mardi, mai 3, 2022
Solution, YouTube, Instagram, Twitter, Health, Infliximab, Report, GLOBE, LLC, Gold Seal, LPM, Joint Commission, Pioneer, Patient, Patient safety, RightNow Technologies, Organization, Accreditation, Overalls, Pharmacist, URAC, CSP, Vaccine, LinkedIn, Pharmacy, CEO, Hospital, Medicine, MD, Facebook, Incircle and excircles of a triangle

TEMECULA, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Nufactor, Inc., a specialty infusion company and subsidiary of FFF Enterprises Inc., is pleased to announce that it has been named a 2021 Pioneer in the URAC Leaders in Performance Measurement (LPM) recognition program.

Key Points: 
  • TEMECULA, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Nufactor, Inc., a specialty infusion company and subsidiary of FFF Enterprises Inc., is pleased to announce that it has been named a 2021 Pioneer in the URAC Leaders in Performance Measurement (LPM) recognition program.
  • "Nufactor is proud to be recognized by our accrediting body URAC with its Pioneer award.
  • URAC's Pioneer award recognizes organizations that have made significant contributions to improving performance measurement within accreditation programs.
  • "Through the introduction of our Leaders in Performance Measurement program, URAC is recognizing the commitment of URAC-accredited organizations who are promoting trust in the quality of care delivered through performance measurement activities," says Shawn Griffin, MD, president, and CEO.

Inflectra Hosts In-Person Event to Increase Education in the Software Management Lifecycle

Retrieved on: 
Mercredi, avril 27, 2022
CEO, Automation, DevOps, API, Gallaudet University, Leadership, Lightning, Conference, Technology, Alphabet soup, Solution, Spira, Certification, Name, Time, Management, Infliximab

WASHINGTON, April 27, 2022 /PRNewswire/ -- Inflectra, a leading maker of IT Software Lifecycle Management Solutions, today announced that it will host InflectraCON 2022 in collaboration with software test professionals and STPCon. The two-day, multi-track conference will take place on May 5-6, at the Kellogg Conference Center at Gallaudet University in Washington D.C. Attendees will learn about the newest programs in software development, testing, agile, DevOps, cyber, leadership, and innovation space. The conference will also feature a robust training and certification component for the users of Inflectra's award-winning platforms Spira and Rapise.

Key Points: 
  • WASHINGTON, April 27, 2022 /PRNewswire/ -- Inflectra , a leading maker of IT Software Lifecycle Management Solutions, today announced that it will host InflectraCON 2022 in collaboration with software test professionals and STPCon.
  • The conference will also feature a robust training and certification component for the users of Inflectra's award-winning platforms Spira and Rapise.
  • "We are honored to host some of the biggest names in the software industry at an event that will provide unique perspectives on their careers."
  • Its industry-leading products for application test management, test automation, and lifecycle management help customers streamline their operations, allowing developers, testers and managers to allocate their time and resources to business-critical assignments.

Galapagos publishes 2021 annual report and announces extraordinary and annual shareholders’ meetings

Retrieved on: 
Jeudi, mars 24, 2022
Diepenbeek, SEC, CSO, CEO, MD, Time, Fibrosis, Company, University, Proxy, Association, Dermatology, Health, Institute, Policy, Pharmacy, Rale, Medicine, Rheumatology, Letter, NASDAQ, Société Nationale de Crédit et d'Investissement, Solar Total Energy Project, Remuneration, Annual report, CFO, Government, Review, Bernhard Nocht Institute for Tropical Medicine, Inflammation, PDF, Gettysburg College, Patient, Total, Exercise, CET, University of Antwerp, Euronext, Retirement, Infection, Tropical medicine, Valeo, Immunology, COVID-19, VP, HIV, Galapagos NV, Ustekinumab, Executive Committee, Acquisition, Johnson & Johnson, Commission Supérieure des Comptes, Medical device, Management, Pharmaceutical industry, Janssen, Galápagos Islands, Infliximab, Veolia, Biology, ENSAE, Sanofi, Virco

Mechelen, Belgium; 24 March 2022, 21.01 CET; regulated information Galapagos NV (Euronext & NASDAQ: GLPG) published its annual report for the financial year 2021 and announces extraordinary and annual shareholders meetings to be held sequentially on Tuesday 26 April 2022 at 1:00 p.m. (CET) and 2:00 p.m. (CET), respectively, at the registered office of the Company.

Key Points: 
  • Mechelen, Belgium; 24 March 2022, 21.01 CET; regulated information Galapagos NV (Euronext & NASDAQ: GLPG) published its annual report for the financial year 2021 and announces extraordinary and annual shareholders meetings to be held sequentially on Tuesday 26 April 2022 at 1:00 p.m. (CET) and 2:00 p.m. (CET), respectively, at the registered office of the Company.
  • The annual report for the financial year 2021, including a review of figures and performance, is available online at https://www.glpg.com/financial-reports and can also be downloaded as PDF.
  • The convening notice and other documents pertaining to the shareholders meetings can be consulted on our website, www.glpg.com/shareholders-meetings .
  • We are monitoring the situation closely and will, if necessary, disclose additional relevant information and measures affecting the shareholders meetings on the Galapagos website ( https://www.glpg.com/shareholders-meetings ).

Biosimilar Monoclonal Antibodies Market worth $ 36.85 Billion by 2030 - Exclusive Report by InsightAce Analytic

Retrieved on: 
Mercredi, mars 23, 2022
CAGR, Ranibizumab, Conditional sentence, Eculizumab, Degenerative disease, Kidney failure, Patent, Partnership, Genentech, Growth, Clinical trial, European Medicines Agency, HER2, Research, Infliximab, Rituximab, Mab, Cancer, Psoriasis, Bevacizumab, Cetuximab, Bangalore, Government, Denosumab, Adalimumab, Boehringer Ingelheim, Safety, Rheumatoid arthritis, Diabetes, Knowledge, Neutralizing antibody, EMEA, GMP, FDA, Breast cancer, Patient, Pharmaceutical industry, Fine chemical, Generic drug, Allergan, Trastuzumab, Trastuzumab, Celltrion, Pfizer, Biocon, Product

According to the latest research, the global biosimilar monoclonal antibodies market is valued at US$ 4.98 Billion in 2021, and it is expected to reach US$ 36.85 Billion by 2030, with a CAGR of 25% during the forecast period of 2022-2030.

Key Points: 
  • According to the latest research, the global biosimilar monoclonal antibodies market is valued at US$ 4.98 Billion in 2021, and it is expected to reach US$ 36.85 Billion by 2030, with a CAGR of 25% during the forecast period of 2022-2030.
  • They are equivalent in terms of quality, efficacy, and safety to an innovative reference medicinal product.
  • Increased patent expiries of top-selling antibodies have encouraged pharmaceutical companies to develop biosimilars for mAbs, likely to accelerate the market during the forecast period.
  • Global Biosimilar Monoclonal Antibodies Market, by Product, 2020-2030 (Value US$ Mn)

Biosimilar Monoclonal Antibodies Market worth $ 36.85 Billion by 2030 - Exclusive Report by InsightAce Analytic

Retrieved on: 
Mercredi, mars 23, 2022
CAGR, Ranibizumab, Conditional sentence, Eculizumab, Degenerative disease, Kidney failure, Patent, Partnership, Genentech, Growth, Clinical trial, European Medicines Agency, HER2, Research, Infliximab, Rituximab, Mab, Cancer, Psoriasis, Bevacizumab, Cetuximab, Bangalore, Government, Denosumab, Adalimumab, Boehringer Ingelheim, Safety, Rheumatoid arthritis, Diabetes, Knowledge, Neutralizing antibody, EMEA, GMP, FDA, Breast cancer, Patient, Pharmaceutical industry, Fine chemical, Generic drug, Allergan, Trastuzumab, Trastuzumab, Celltrion, Pfizer, Biocon, Product

According to the latest research, the global biosimilar monoclonal antibodies market is valued at US$ 4.98 Billion in 2021, and it is expected to reach US$ 36.85 Billion by 2030, with a CAGR of 25% during the forecast period of 2022-2030.

Key Points: 
  • According to the latest research, the global biosimilar monoclonal antibodies market is valued at US$ 4.98 Billion in 2021, and it is expected to reach US$ 36.85 Billion by 2030, with a CAGR of 25% during the forecast period of 2022-2030.
  • They are equivalent in terms of quality, efficacy, and safety to an innovative reference medicinal product.
  • Increased patent expiries of top-selling antibodies have encouraged pharmaceutical companies to develop biosimilars for mAbs, likely to accelerate the market during the forecast period.
  • Global Biosimilar Monoclonal Antibodies Market, by Product, 2020-2030 (Value US$ Mn)

Health Canada Approves Samsung Bioepis and Biogen’s BYOOVIZ™ (SB11), LUCENTIS® Biosimilar (ranibizumab)

Retrieved on: 
Jeudi, mars 10, 2022
Risk, Pharmacokinetics, CADTH, Neuroscience, Central retinal vein occlusion, CNV, Diabetic retinopathy, Samsung, Nobel Prize, LinkedIn, Safety, AMD, United Kingdom, Infliximab, Regulatory affairs, GLOBE, Patient, NOC, Macular edema, Neovascularization, RVO, Biotechnology, Inclusion, Lists of diseases, Health Canada, Pathology, General manager, Endocrinology, Culture, Visual impairment, Trastuzumab, Treatment, Ophthalmology, Multiple sclerosis, Hematology, Twitter, Ranibizumab, Adalimumab, Spinal muscular atrophy, Severe cognitive impairment, Bevacizumab, Gastroenterology, Choroidal neovascularization, Social media, Biosimilar, Health care, Genentech, DME, Generic drug, Pharmaceutical industry, Health insurance, EU, Biogen, Woman

Health Canada granted a Notice of Compliance (NOC) for BYOOVIZ on March 8, making it the first and only ranibizumab biosimilar to receive regulatory approval in Canada to date.

Key Points: 
  • Health Canada granted a Notice of Compliance (NOC) for BYOOVIZ on March 8, making it the first and only ranibizumab biosimilar to receive regulatory approval in Canada to date.
  • The approval is part of our commitment to providing a treatment option for patients with retinal vascular disorders in Canada.
  • The Health Canada approval was based on a totality of evidence including quality, non-clinical data, and clinical data.
  • In November 2019, Samsung Bioepis signed a commercialization agreement with Biogen Inc. for two ophthalmology biosimilar candidates, SB11 (ranibizumab) and SB15 (aflibercept).

Inflectra Launches Its Virtual Learning Platform

Retrieved on: 
Mardi, mars 1, 2022
Certification, Agile, DevOps, QA, Hand, Quality assurance, Solution, API, Student, Project management, Faculty, CEO, Medical device, Management, Harmony, Infliximab

WASHINGTON, March 1, 2022 /PRNewswire/ --Inflectra - a leading maker of IT Software Lifecycle Management Solutions announced the launch of its Virtual Learning and Certification Platform - Inflectra Campus.

Key Points: 
  • WASHINGTON, March 1, 2022 /PRNewswire/ --Inflectra - a leading maker of IT Software Lifecycle Management Solutions announced the launch of its Virtual Learning and Certification Platform - Inflectra Campus.
  • Inflectra Campus hosts a series of on-demand courses for its most popular platforms: SpiraPlan , KronoDesk, and Rapise.
  • "Inflectra Campus, together with our long-standing Inflectra Global Technology Initiative, is our humble attempt to give back to the tech communities across the globe.
  • Free training courses offered through this virtual learning platform go hand in hand and complement our work with academic institutions worldwide, where we provide classroom editions of our platforms as learning tools free of charge.